

Contents

Chapter I: Recent Developments of the Histamine Problem

Section A: Pharmacological Actions

1. Cardiovascular Actions of Histamine. B. M. ALTURA and S. HALEVY. With 3 Figures

I. Introduction	1
II. Systemic Vascular Effects of Histamine	2
A. Rat	2
B. Guinea-Pig	2
C. Rabbit	3
D. Dog	3
E. Cat	3
F. Calf, Horse, and Sheep	7
G. Man	7
III. Cardiac Actions of Histamine	7
A. Intact Animals	11
1. Inotropic Action	11
2. Chronotropic Action	11
3. Dromotropic Action	11
4. Cardiac Output	11
B. Isolated Heart Preparations	12
1. Inotropic Action	12
2. Chronotropic Action	12
3. Dromotropic Action	12
4. Coronary Flow	13
IV. Effects of Histamine on Regional Vasculatures	13
A. Coronary	13
B. Pulmonary Lung	21
C. Splanchnic	21
D. Liver-Portal	22
E. Renal	22
F. Musculo-Cutaneous	22
G. Cerebral	22
H. Miscellaneous	22
V. Microcirculatory Actions of Histamine	22
A. Direct In-Vivo Microcirculatory Actions of Histamine	24
B. H_1 Versus H_2 -Receptors in Microcirculation	25
C. Effects of Histamine on Vascular Permeability and Endothelial Cells	26

VI. Isolated Vascular Smooth Muscle and Histamine	27
VII. Conclusions	29
References	30

2. Histamine and Gastric Secretion. L.R.JOHNSON. With 7 Figures

I. Introduction	41
II. Historical Review	41
III. Physiologic Evidence	43
A. Histidine Decarboxylase Activation	43
B. Histamine Release and Gastric Secretion	46
IV. H ₂ -Receptor Antagonists: Gastric Secretion and the Role of Histamine	49
V. Conclusions	54
References	55

Section B: Histamine Release

1. On the General Problem of the Release of Histamine. A.GOTH

I. Introduction	57
II. The Noncytotoxic Nature of Histamine Secretion	58
III. Histamine Release and Complement	60
IV. The IgE Receptor	60
V. Control Mechanisms of Histamine Release	61
Cyclic Nucleotides and Histamine Release	61
VI. Enhancers and Inhibitors of Histamine Release	62
A. Enhancers of Histamine Release	62
1. Phosphatidyl Serine	63
2. Deuterium Oxide (D ₂ O)	63
3. Cholinergic Stimulation	64
B. Inhibitors of Histamine Release	64
1. The Role of Calcium in Histamine Release	65
2. Desensitization	66
VII. Histamine Release from Tissues and Platelets	67
A. Histamine Release from Isolated Tissues and Organs	67
B. Histamine Release from Platelets	67
VIII. Concluding Remarks	68
References	69

2. The Mechanism of Histamine Release from Mast Cells. B.UVNÄS. With 9 Figures

I. Introduction	75
II. The Normal Mast Cells	75
A. Morphology	75
B. Contents	78

III. The Degranulating Mast Cell	78
A. Degranulating Agents	78
B. Noncytotoxic Character of the Degranulation Process	79
C. Electron-Microscopic Changes	79
IV. Storage Properties of Basophil Granules	82
A. Role of Heparin	82
B. Role of Zinc	83
C. Role of the Granule Protein-Heparin Complex	84
V. Relationship Between Degranulation and Histamine Release	87
References	90

3. Metabolic Changes in Mast Cells Associated with Histamine Release.

N. CHAKRAVARTY. With 8 Figures

I. Energy Dependence of Anaphylactic Histamine Release	93
II. Energy Metabolism of Mast Cells	95
III. Changes in Mast Cell Respiration in Relation to Histamine Release	97
IV. Changes in Glucose Metabolism in Mast Cells Associated with Histamine Release	98
V. Changes in Adenosine Triphosphate Content of Mast Cells Associated with Histamine Release	101
VI. Conclusion	105
References	106

Section C: Metabolism and Excretion of Histamine

1. Biogenesis of Histamine. R. W. SCHAYER

I. Introduction	109
II. Methods for Determination of Histidine Decarboxylase Activity of Mammalian Tissues	109
III. Histamine Formation in vitro	110
IV. Histamine Formation in vivo	113
V. Inhibition of Histamine Formation in vitro	115
VI. Inhibition of Histamine Formation in vivo	117
VII. Histidine Decarboxylase Activation and Deactivation; Role of Protein and RNA Synthesis	118
VIII. Effect of Hormones on Histamine Formation	119
IX. Histamine Formation in Brain	119
X. Histamine Formation and Antihistamines	121
XI. Conclusion	122
References	122

2. Histamine Metabolism and Excretion. H. WETTERQVIST

I. Histamine Metabolism in Tissues	132
II. Changes in Histamine Metabolism in Tissues	133
III. Histamine Metabolism and Excretion in Animals	134
A. Rat	134
B. Mouse	135
C. Guinea Pig	135
D. Hamster	136
E. Rabbit	136
F. Sheep	136
G. Goat	136
H. Pig	137
I. Cow	137
J. Horse	137
K. Cat	137
L. Toad, Tortoise, Terrapin	137
IV. Changes in Histamine Metabolism and Excretion in Animals	137
V. Histamine Metabolism in Human Tissues	139
VI. Histamine Metabolism and Excretion in Man	139
VII. Changes in Histamine Metabolism and Excretion in Man	140
VIII. Blood Diseases	142
IX. Allergy	142
X. Burns	142
XI. Miscellaneous	143
XII. Comments	143
References	143

3. The Enzymatic Isotopic Assay of Histamine. M. A. BEAVEN and Z. HORAKOVA. With 3 Figures

I. Introduction	151
A. Principle of Isotope Derivative Dilution Assays	151
B. Applications of Isotope Derivative Dilution Analysis in Biological Work	152
C. Enzymatic Isotope Derivative Dilution Assays	153
II. Double Isotope Assay (with β - 3 H-Histamine as Internal Standard)	154
A. Principle	154
B. Chemicals	154
C. Preparation of β - 3 H-(side-chain label)-Histamine	155
D. Preparation of Histamine-N-Methyltransferase	155
E. Storage and Preparation of Samples for Analysis	156
F. Reagents and Stock Solutions (in Order of Use)	157
G. Incubation Procedure	157
H. Extraction and Measurement of Labeled Methylhistamine	158
I. Calculation	159
J. Comments	160

III. Single Isotope Microenzymatic Assay of Histamine	161
A. Introduction	161
B. Chemicals	161
C. Reagents	161
D. Procedure	161
E. Calculation	162
F. Comments	162
IV. General Precautions to Be Observed with Enzymatic Assays of Histamine	162
A. Specificity of Assay	162
B. Assay Blanks and Precision of Assay	162
C. Extraction Procedure and Use of Unlabeled Methylhistamine as Carrier	163
D. Interference from Drugs and Tissue Constituents	163
E. Importance of Purity of Labeled SAMe	164
V. Use of Enzymatic Assay in Measurement of Histamine, L-Histidine, and Histamine-Metabolizing Enzymes in Tissues	164
A. Histamine	164
B. Assay of Histidine	169
C. Histidine Decarboxylase	170
D. Assay of Histamine-N-Methyltransferase	170
References	171

Chapter II: Chemistry and Structure-Activity Relationships of Synthetic Anti-Histaminics

Section A: Chemistry of Anti-H ₁ Histamine Antagonists. A.F.CASY. With 2 Figures	
I. Introduction	175
II. Chemical Types of H ₁ -Antihistaminic Drugs	179
A. Early Work	179
B. Ethylenediamines	179
C. Tertiary-aminoalkyl Ethers	182
D. 1,2-Diaryl-4-Aminobutenes	185
E. 1,1-Diaryl-3-Aminopropenes	189
F. 3-Amino-1-Aryl-1-(2-Pyridyl)Propanes(Pheniramines)	193
G. Phenothiazine Derivatives	196
H. Further Tricyclic Derivatives	198
I. Miscellaneous Types	202
References	207

Section B: Structure-Activity Relationships of H₁-Receptor Antagonists.

W.Th.NAUTA and R.F.REKKER. With 2 Figures

I. Introduction	215
II. Compilation of the Most Important Structures with Anti-H ₁ Activity. Classification of the Structures Considered and Review of Measured Anti-H ₁ Activities	216

III. Physical Properties and Anti-H ₁ Activity	227
A. Qualitative Drug Design Based on the Physical Properties of Structures	227
1. Ionization Constants	227
2. Solubilities	227
3. Surface Properties	228
4. Spectral Data	228
5. Bond Stabilities	229
6. Charge Localizations	229
7. Dipole Moments	230
B. Quantitative Design. The Hansch Approach	231
1. Introduction	231
2. The Hansch Approach Applied to a Series of Ring-Substituted Diphenhydramine Derivatives	232
3. The Hansch Approach Applied to a Series of Diphenhydramines with the Nitrogen Atom Included in a Ring System	232
4. The Activities of 1,1-Diaryl-3-Aminopropenes, and Some Related Compounds	233
C. Some Features of Anti-H ₁ Activity Connected with Stereospecificity. Conformational Preferences	234
1. Anti-H ₁ Activities of Structures with an Optically Active Center .	234
2. Anti-H ₁ Activities of Cis-Trans Isometric Structures	239
3. The Inclusion of Optically Active Structures into the Hansch Approach	239
D. Integrated QSAR of H ₁ -Receptor Antagonists	240
IV. Conclusion	245
References	245

Section C: Chemistry and Structure-Activity Relationships of H₂-Receptor Antagonists.
C.R. GANELLIN. With 17 Figures

I. Introduction	251
II. Development of H ₂ -Receptor Antagonists	253
A. The Search for an Antagonist	253
B. Development of Burimamide	256
C. Development of Metiamide	260
D. Development of Cimetidine	265
III. Chemical Constitution	267
A. Introduction	267
B. Burimamide and Metiamide	267
C. Cimetidine	274
IV. Chemical Mode of Action	277
V. Pharmacokinetics	280
A. Absorption and Distribution	280
B. Metabolism and Elimination	281

VI. Chemical Differentiation Between H ₁ - and H ₂ -Receptor Antagonists	283
VII. Synthesis of Burimamide, Metiamide, and Cimetidine	285
References	287

Chapter III: Mechanism of Action of Antihistaminics

Section A: Kinetics of Antagonist Action. M. ROCHA E SILVA. With 21 Figures

I. The Charnière Theory	295
II. Applications of the Theory	312
III. Appendix	326
References	329

Section B: Competitive and Noncompetitive Antagonism. FRANS G. VAN DEN BRINK and ERIC J. LIEN. With 11 Figures

I. Introduction	333
II. Material and Methods	334
A. Test Organs	334
B. Affinity and Intrinsic Activity Values	334
C. Test Substances	335
III. Results and Discussion	340
A. Closer Inspection of the Intrinsic Activity and Affinity Values in Table 1	340
1. Intrinsic Activity and Affinity Values of Partial Agonists	340
2. pA ₂ -Values Based on a Smaller Number of Animals than the Accompanying pD ₂ -Values, and Vice Versa	341
B. The Interaction of Agonists and Competitive Antagonists with the Histamine Receptors; the Role of Additional Receptor Areas	342
C. Competitive Antagonists and Their Affinity to the Metactoid Receptor	345
1. The pA ₂ /pD ₂ -Ratios in the Histaminergic System	345
2. The pA ₂ /pD ₂ -Ratios in the Cholinergic System	349
3. Comparison of the pD ₂ -Values in the Histaminergic and the Cholinergic System	350
D. Influence of Some Molecular Modifications on the Affinity Values	351
1. The Influence of the Substitution of a Methyl Group to the Secondary N-Atom. The "Rule of Pfeiffer"	351
2. The Influence of the Presence or Absence of an N-Atom in the Ring in the "Mimetic Moiety" (Pyridyl or Phenyl Ring)	353
3. The Influence of Para-Substitution of a Cl-Atom at the Phenyl Ring in the N-phenyl-N-benzyl-ethylamine Group	354
4. The Influence of Para-Substitution at the Phenyl Ring of N-(N'-phenyl-N'-benzyl-β-aminoethyl)-N-methyl-{2-(β-aminoethyl)-pyridine}	355

E. Quantitative Structure-Activity Correlations of 2-(β -aminoethyl)-pyridines	360
F. Pitfalls in Structure-Activity Relationship Studies	363
References	366

Section C: Naturally Occuring Antihistaminics in Body Tissues. G. PELLETIER.
With 1 Figure

I. Introduction	369
II. Methods of Extraction of Antihistamine Activity	370
General Considerations	371
III. Methods of Assay of Natural Antihistamine Substance(s) (NAS)	371
Units of Activity	372
IV. Estimation of Antihistamine Activity in Mammals	372
V. Modifications of Amount of NAS Present in Tissues and Fluids	372
A. Elevation of NAS	374
B. Diminution of NAS	375
VI. Mechanism of Action of NAS	375
VII. Physical and Chemical Aspects of NAS	376
A. Molecular Weight	376
B. Solubility	376
C. Stability	377
D. Chemical Structure	377
VIII. Role of NAS	377
References	378

Chapter IV: Pharmacological Actions of Antihistaminics

Section A: Bioassay of Antihistaminic Action. M. ROCHA E SILVA and A. ANTONIO.
With 7 Figures

I. Introduction	381
II. In Vitro Assays for Antihistaminics	391
A. Assays on the Guinea Pig Ileum and Other Smooth Muscle Structures	391
B. On the Schultz-Dale Reaction of the Sensitized Strips of the Guinea Pig Ileum and Uterus	399
C. Bioassay of Antihistaminics on the Isolated Mammalian Heart	400
D. Interrelations Between Antihistaminics and the Histamine(H ₁)Receptors	402
III. In Vivo Assays of Antihistaminics	405
A. Protection Against the Lethal Effects of Histamine	405
B. Protection Against Asthma (Bronchospasm) Produced by Inhalation of a Histamine Aerosol	406

C. Protection of Sensitized Guinea Pigs Submitted to the Challenging Dose of the Antigen	411
D. Atropine-like Effects of Antihistaminics	413
E. Local Anesthetic Action of Antihistaminics	417
F. Action on the Skin Vessels and on Vascular Permeability	420
IV. Conclusions	424
References	425

Section B: Antianaphylactic and Antiallergic Effects. F. HAHN

I. Introduction	439
II. General Aspects of Antianaphylactic and Antiallergic Effects of Antihistaminics	440
A. Receptor Specificity	440
B. Potency of Antihistaminics	441
C. Effect of Antihistaminics on Endogenously Released Histamine	441
D. Nonspecific Effects of Antihistaminics	442
III. Effects of Antihistaminics on Guinea Pig Anaphylaxis	445
A. Systemic Shock	445
1. Antilethal Effects	445
2. Effect of Antihistaminics on Bronchospasm in vivo	452
B. Action of Antihistaminics in Isolated Organs	453
1. Lung and Trachea	453
2. Isolated Gut	455
3. Uterus	456
4. Striated Muscle	456
C. Heart Anaphylaxis	456
D. Heart-Lung Preparation (HLP)	461
E. Adrenals and Adrenergic System	461
1. Role of Catecholamine Release in the Antianaphylactic Action of Antihistaminics on Acute Shock	461
2. Protracted Shock and Adrenal Glands	464
F. Action of Antihistaminics on Antigen Aerosols	465
G. Action of Antihistaminics on Cutaneous Anaphylaxis	466
H. Forssman Shock	467
I. Miscellaneous	468
IV. Anaphylaxis in Dogs	469
V. Anaphylaxis in Rabbits	470
VI. Anaphylaxis in Rats	471
VII. Anaphylaxis in Mice	474
VIII. Other Species	475
Summary and Conclusions	478
References	480

Section C: Antiinflammatory Effects. C. G. Van ARMAN

I. Recent Work Involving H ₂ -Receptors	505
II. Effect of Antiinflammatory Drugs on the Interactions of Histamine with Other Possible Mediators of Inflammation	506
III. Implications of Antiinflammatory Drugs for Elucidating Possible Roles of Histamine	508
A. In Anaphylactic Shock	508
B. In Allergy	509
C. Responses of Tracheal Muscle	509
IV. Inflammations in Which Antihistaminics Have Little or No Effect	510
V. Evidence from Depletion Experiments	510
References	510

Chapter V: Absorption, Distribution, Metabolism, and Elimination of Antihistamines. D. T. WITIAK and N. J. LEWIS

I. Early Studies of Antihistamine Distribution, Excretion, and Metabolism	513
II. Diphenhydramine and Orphenadrine	516
III. Tripelennamine Metabolism	523
IV. Cyclizine, Chlorcyclizine, and Related Compounds	526
V. Chlorpheniramine and Brompheniramine	532
VI. Chlorphenesin, Chlorphenesin Carbamate, and Related Phenoxy Propanediols	535
VII. Perazine, Prochlorperazine, Trifluperazine, and Fluphenazine	537
VIII. Promethazine, Chlorpromazine, and Related Compounds	538
IX. Cyproheptadine, Amitriptyline, Nortriptyline, and Protriptyline	543
X. Doxepin	546
XI. Hepzidine	547
XII. Drug Metabolism and Enzyme Induction	549
XIII. H ₂ Histamine Antagonists	552
References	554

Chapter VI: Therapeutic Action of Anti-Histaminics**Section A: Antihistaminics as Central Nervous System Depressants. C. L. FAINGOLD. With 1 Figure**

I. Introduction	561
II. Laboratory Studies	561
A. Behavioral Studies	562
B. Drug Interaction Studies	562
C. EEG Studies	562
III. Clinical Studies	563
A. Ethylenediamine Agents	563
B. Alkylamine Agents	565

C. Piperazine Agents	565
D. Phenothiazine Agents	566
E. Aminoalkyl Ether Agents	566
IV. Mechanism of Action	567
References	570
 Section B. Circulatory Shock, Histamine and Antihistamines: Therapeutic Aspects.	
B.M. ALTURA and S. HALEVY	
I. Introduction	575
II. Vasoactive Agents: Use and Misuse in Low-Flow States	577
III. Failure of Peripheral Vascular-Homeostatic Mechanisms	580
IV. Vasoactive Mediators in Circulatory Shock	581
V. Is Histamine the Mediator of the Shock Syndrome?	584
VI. Plasma Histamine Levels in Man and Animals in Shock	585
A. Hemorrhage	586
B. Trauma	587
C. Endotoxemia-Sepsis	587
D. Burns-Scalding	587
E. Anaphylactic Shock	588
VII. Influence of Antihistamines on Survival after Circulatory Shock	588
A. Histamine Shock	589
B. Hemorrhage	589
C. Trauma	592
D. Endotoxemia-Sepsis	593
E. Burns-Scalding	593
F. Anaphylactic Shock	594
VIII. Conclusions and Future Outlook for Antihistamine Therapy in Circulatory Shock and Low-Flow States	594
References	594
 Author Index	603
Subject Index	655